Corbus Pharmaceuticals Holdings (CRBP) EBITDA (2013 - 2025)

Corbus Pharmaceuticals Holdings has reported EBITDA for 13 years, with the latest figure at -$24.4 million in Q3 2025.

• On a quarterly basis, EBITDA fell 57.48% year-over-year to -$24.4 million in Q3 2025; TTM through Sep 2025 was -$75.9 million, a 64.32% decrease from a year earlier, with the FY2024 full-year figure at -$48.7 million, down 8.08% from the prior year.
• EBITDA was -$24.4 million for Q3 2025 at Corbus Pharmaceuticals Holdings, down from -$19.2 million in the prior quarter.
• The five-year high for EBITDA was -$8.2 million in Q3 2022, with the low at -$24.4 million in Q3 2025.
• Average EBITDA over 5 years is -$13.3 million, with a median of -$12.3 million recorded in 2022.
• The sharpest annual moves came in 2021 and 2025: EBITDA soared 59.16% in 2021, then tumbled 105.5% in 2025.
• Over 5 years, EBITDA stood at -$10.0 million in 2021, then decreased by 7.99% to -$10.8 million in 2022, then advanced by 6.42% to -$10.1 million in 2023, then fell by 24.75% to -$12.6 million in 2024, then sank by 93.71% to -$24.4 million in 2025.
• The last three EBITDA figures came in at -$24.4 million (Q3 2025), -$19.2 million (Q2 2025), and -$19.8 million (Q1 2025), per Business Quant data.